Someone at Novo Nordisk forgot (or failed) to pay a $450 patent maintenance fee—a tiny sum in the world of pharma—on Ozempic, one of the company's biggest blockbusters.
This single slip meant the patent lapsed two years early, potentially opening the floodgates to generics and shaving years off of exclusivity.
💸 In a sector where patent timing is everything, this could turn out to be one of the most expensive clerical errors in recent memory.
A sharp reminder that ops excellence matters just as much as innovation.
P.S. Exploring the O1, EB2 NIW, or EB1A? Get a free evaluation today – https://lnkd.in/eXBcg6bt
P.P.S Exploring the EB5 Investor Green Card? Book a strategy call – https://lnkd.in/en9Abaaw
Credit: Caleb Whitney
Pharma Patents OperationalExcellence Ozempic NovoNordisk MistakesMatter
This post was originally shared by on Linkedin.